On August 28, BioNTech SE declined 11.62% in pre-market trading, trading at approximately $99.0/share, with turnover of $4.38 million.

On the news front, Pfizer and BioNTech announced that the FDA approved their 2026-2027 COVID-19 vaccine targeting the XFG variant, but the authorized population was limited to adults aged 65 and older and individuals aged 5 through 64 with at least one underlying high-risk condition. This represents a significant narrowing from prior years when vaccines were authorized for the general population, raising concerns over future COVID-19 vaccine revenue potential.

The restricted approval compounds existing fundamental pressures. In Q2 results reported on August 4, BioNTech posted an adjusted loss of 2.22 euros per share, worse than the consensus estimate of 1.99 euros loss, while revenue of 105.6 million euros missed the expected 157.8 million euros. The company also cut its full-year 2026 revenue guidance to 1.60-1.90 billion euros, well below the analyst consensus of 2.16 billion euros. The combination of a deteriorating earnings trajectory and a materially restricted vaccine approval has weighed heavily on investor sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)